Malignant Pleural Effusion Interventions: What Matters Most to the Patient?

Share this content:
Patients with malignant pleural effusion may care more about relieving symptoms such as dyspnea as opposed to achieving pleurodesis.
Patients with malignant pleural effusion may care more about relieving symptoms such as dyspnea as opposed to achieving pleurodesis.

Competing risk analysis, as used in AMPLE-2, is a superior approach in this setting, according to Dr Ost. "A plot of the cumulative incidence function would show that initially the groups split apart but the patients with a trapped lung would eventually catch up so the curves would merge," Dr Ost wrote.3 "However, the curves are not the same so concluding there is no difference would be incorrect." The competing risk model is more complete because it considers all available information.

In addition, survival analysis techniques more accurately reflect the timing of pleurodesis. Because of differences in the length of time between drainage in the 2 groups in AMPLE-2, pleurodesis would be detected at a maximum of 3 days in the daily drainage group compared with 2 to 4 weeks in the symptom-guided group. With the use of single time point incidence proportions, it would be difficult to determine whether 1 drainage strategy leads to earlier pleurodesis.3

Continue Reading Below

However, with competing risk analysis, one can "quickly inspect the cumulative incidence function curves and see that, even after accounting for up to a 4­ week delay in detection, pleurodesis rates favor aggressive drainage," explained Dr Ost. "The use of survival analysis techniques for studies of malignant pleural effusion should become the standard."

Dr Ost also noted that patient concerns pertain to freedom from breathlessness and quality of life rather than pleurodesis, and it is important to evaluate the balance between dyspnea relief, pleurodesis, pain, and the influence of these various factors on quality of life. Although an intervention may increase pain, for example, it may also improve quality of life as a result of dyspnea relief. At this time, it appears that "[t]his type of study design, measuring multiple relevant patient-centered outcomes along with a measure of utility tracked longitudinally is an effective method for gaining a more nuanced insight into the merits of competing strategies."

In practice, however, management strategies should be individualized to each patient. When patients are unsure of their preference regarding drainage strategy, Dr Ost suggests starting with daily drainage for 1 week, followed by the symptomatic approach if drainage does not decrease with the daily approach. This allows patients to choose the strategy that works best for them.

"The goal of shared decision making is optimizing the patient's quality of life, rather than optimizing the quality of life of a population," Dr Ost concluded. "Well-designed studies such as this one can inform the decision but require insight when applied at the bedside."


  1. Aydin Y, Turkyilmaz A, Intepe YS, Eroglu A. Malignant pleural effusions: appropriate treatment approaches. Eurasian J Med. 2009;41(3):186-193.
  2. Muruganandan S, Azzopardi M, Fitzgerald DB, et al. Aggressive versus symptom­guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE­2): an open­label randomised trial. Lancet Respir Med. 2018; 6(9):671-680.
  3. Ost DE. Quantifying outcomes for palliative pleural interventions. Lancet Respir Med. 2018;6(9):648-649.3.
Page 2 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs